Trial Profile
Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2016
Price :
$35
*
At a glance
- Drugs Lidocaine (Primary) ; Nifekalant (Primary)
- Indications Ventricular fibrillation; Ventricular tachycardia
- Focus Therapeutic Use
- Acronyms RELIEF
- 18 Mar 2009 New trial record.